Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-0520 gel for EGFR inhibitor-induced folliculitis
2024-516339-28-00Phase 2Authorised
- Sponsor
- Tarian Pharma
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of brimonidine in folliculitis (2 arms), sponsored by Tarian Pharma. Primary endpoint: Incidence of adverse events, adverse events of special interest, and serious adverse events. Planned start Feb 2025; status: authorised.
02
Drugs
brimonidine
03
Conditions
folliculitis
Beyond the preview
Go deeper on 2024-516339-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516339-28-00.